---
figid: PMC8108463__13059_2021_2357_Fig3_HTML
figtitle: Endogenous retroviruses in the origins and treatment of cancer
organisms:
- NA
pmcid: PMC8108463
filename: 13059_2021_2357_Fig3_HTML.jpg
figlink: /pmc/articles/PMC8108463/figure/Fig3/
number: F3
caption: 'ERVs contribute to oncogenesis and may be targeted therapeutically. a Onco-exapted
  ERVs can regulate host gene expression in tumors. Hypomethylated ERV LTRs can be
  bound by transcription factors (TF) and serve as alternative promoters to induce
  the expression of oncogenes contributing to oncogenesis (top). They may also be
  decorated with H3K27ac and H3K4me1 (light green) and act as enhancers to drive the
  expression of adjacent or distal genes (bottom). Note: empty white circles represent
  unmethylated CpG dinucleotides. b HERV proteins, such as Env, can be expressed from
  intact HERV provirus ORFs in cancer cells (left). In breast and endometrial carcinoma
  models, Env has been detected on the cell membrane and is able to mediate cellular
  fusion with endothelial cells [, ] (middle). Env can promote tumorigenesis, for
  example by stimulating the RAS/RAF/MEK/ERK pathway in breast cancer models []. c
  Proposed model for therapeutic targeting of ERV-induced viral mimicry to promote
  immune detection of tumor cells. ERV reactivation can be induced by a number of
  therapeutic agents that target chromatin modifying enzymes (blue box). Derepression
  of ERV LTRs results in the production of dsRNA molecules, which can be detected
  by cytosolic dsRNA sensors TLR3 and MDA5 [, , ]. MDA5 binds to MAVS in the mitochondria
  and stimulates a signalling cascade which promotes the phosphorylation, dimerisation,
  and nuclear translocation of interferon regulatory factors (IRFs). IRFs drive a
  type I/III interferon response to spur cytokine production and increase the immunogenicity
  of the cell. Viral mimicry synergises with production and presentation of ERV-derived
  tumor associated antigens (green dot) via MHC-I, to increase the visibility of tumor
  cells for immunogenic death by cytolytic T cell activation'
papertitle: Endogenous retroviruses in the origins and treatment of cancer.
reftext: Natasha Jansz, et al. Genome Biol. 2021;22:147.
year: '2021'
doi: 10.1186/s13059-021-02357-4
journal_title: Genome Biology
journal_nlm_ta: Genome Biol
publisher_name: BioMed Central
keywords: ''
automl_pathway: 0.9702998
figid_alias: PMC8108463__F3
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8108463__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8108463__13059_2021_2357_Fig3_HTML.html
  '@type': Dataset
  description: 'ERVs contribute to oncogenesis and may be targeted therapeutically.
    a Onco-exapted ERVs can regulate host gene expression in tumors. Hypomethylated
    ERV LTRs can be bound by transcription factors (TF) and serve as alternative promoters
    to induce the expression of oncogenes contributing to oncogenesis (top). They
    may also be decorated with H3K27ac and H3K4me1 (light green) and act as enhancers
    to drive the expression of adjacent or distal genes (bottom). Note: empty white
    circles represent unmethylated CpG dinucleotides. b HERV proteins, such as Env,
    can be expressed from intact HERV provirus ORFs in cancer cells (left). In breast
    and endometrial carcinoma models, Env has been detected on the cell membrane and
    is able to mediate cellular fusion with endothelial cells [, ] (middle). Env can
    promote tumorigenesis, for example by stimulating the RAS/RAF/MEK/ERK pathway
    in breast cancer models []. c Proposed model for therapeutic targeting of ERV-induced
    viral mimicry to promote immune detection of tumor cells. ERV reactivation can
    be induced by a number of therapeutic agents that target chromatin modifying enzymes
    (blue box). Derepression of ERV LTRs results in the production of dsRNA molecules,
    which can be detected by cytosolic dsRNA sensors TLR3 and MDA5 [, , ]. MDA5 binds
    to MAVS in the mitochondria and stimulates a signalling cascade which promotes
    the phosphorylation, dimerisation, and nuclear translocation of interferon regulatory
    factors (IRFs). IRFs drive a type I/III interferon response to spur cytokine production
    and increase the immunogenicity of the cell. Viral mimicry synergises with production
    and presentation of ERV-derived tumor associated antigens (green dot) via MHC-I,
    to increase the visibility of tumor cells for immunogenic death by cytolytic T
    cell activation'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ltr
  - un
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - te
  - Erk7
  - rl
  - CycE
  - cyc
  - ERVW-1
  - ERVK-20
  - ERVK-18
  - ERVK-32
  - TLR3
  - MAVS
  - IFIH1
  - IRF7
  - IFNK
  - IFNW1
  - IFNA1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA17
  - IFNA21
  - IFNB1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
---
